Literature DB >> 29441369

Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas.

Irvin C Lien1, Seth M Pollack2.   

Abstract

Entities:  

Year:  2018        PMID： 29441369      PMCID： PMC5803027          DOI： 10.21037/tgh.2017.12.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  14 in total

1.  Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages.

Authors:  Qiyi Zhao; Dong-Ming Kuang; Yan Wu; Xiao Xiao; Xue-Feng Li; Tuan-Jie Li; Limin Zheng
Journal:  J Immunol       Date:  2011-12-19       Impact factor: 5.422

2.  Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization.

Authors:  Christine M Barbon; Min Yang; Gregory D Wands; Radha Ramesh; Barbara S Slusher; Mary Lynne Hedley; Thomas M Luby
Journal:  Cell Immunol       Date:  2010-02-12       Impact factor: 4.868

3.  Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.

Authors:  Mikayel Mkrtichyan; Yana G Najjar; Estella C Raulfs; Maher Y Abdalla; Raed Samara; Rinat Rotem-Yehudar; Larry Cook; Samir N Khleif
Journal:  Eur J Immunol       Date:  2011-08-17       Impact factor: 5.532

4.  Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma.

Authors:  Olivier Mir; Julien Domont; Angela Cioffi; Sylvie Bonvalot; Bérénice Boulet; Cécile Le Pechoux; Philippe Terrier; Marc Spielmann; Axel Le Cesne
Journal:  Eur J Cancer       Date:  2011-01-19       Impact factor: 9.162

5.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

Authors:  William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz
Journal:  Lancet       Date:  2016-06-09       Impact factor: 79.321

6.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Authors:  Hussein A Tawbi; Melissa Burgess; Vanessa Bolejack; Brian A Van Tine; Scott M Schuetze; James Hu; Sandra D'Angelo; Steven Attia; Richard F Riedel; Dennis A Priebat; Sujana Movva; Lara E Davis; Scott H Okuno; Damon R Reed; John Crowley; Lisa H Butterfield; Ruth Salazar; Jaime Rodriguez-Canales; Alexander J Lazar; Ignacio I Wistuba; Laurence H Baker; Robert G Maki; Denise Reinke; Shreyaskumar Patel
Journal:  Lancet Oncol       Date:  2017-10-04       Impact factor: 41.316

7.  T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Authors:  Seth M Pollack; Qianchuan He; Jennifer H Yearley; Ryan Emerson; Marissa Vignali; Yuzheng Zhang; Mary W Redman; Kelsey K Baker; Sara Cooper; Bailey Donahue; Elizabeth T Loggers; Lee D Cranmer; Matthew B Spraker; Y David Seo; Venu G Pillarisetty; Robert W Ricciotti; Benjamin L Hoch; Terrill K McClanahan; Erin Murphy; Wendy M Blumenschein; Steven M Townson; Sharon Benzeno; Stanley R Riddell; Robin L Jones
Journal:  Cancer       Date:  2017-05-02       Impact factor: 6.860

8.  PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis.

Authors:  Yi Que; Wei Xiao; Yuan-Xiang Guan; Yao Liang; Shu-Mei Yan; Huo-Ying Chen; Qiao-Qiao Li; Bu-Shu Xu; Zhi-Wei Zhou; Xing Zhang
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

Review 9.  Cancer immunotherapies targeting the PD-1 signaling pathway.

Authors:  Yoshiko Iwai; Junzo Hamanishi; Kenji Chamoto; Tasuku Honjo
Journal:  J Biomed Sci       Date:  2017-04-04       Impact factor: 8.410

10.  Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.

Authors:  Charlotte Roach; Nancy Zhang; Ellie Corigliano; Malinka Jansson; Grant Toland; Gary Ponto; Marisa Dolled-Filhart; Kenneth Emancipator; Dave Stanforth; Karina Kulangara
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-07
View more
  1 in total

1.  Efficacy and safety of toripalimab combined with doxorubicin as first-line treatment for metastatic soft tissue sarcomas: an observational study.

Authors:  Zhiyong Liu; Cuiping Liu; Weitao Yao; Songtao Gao; Jiaqiang Wang; Peng Zhang; Hong Ge
Journal:  Anticancer Drugs       Date:  2021-10-01       Impact factor: 2.248
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.